Clinical Trials Sponsored by Prothya Biosolutions

Total 133 results

Prothya Biosolutions

Completed

Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy

Myocardial Diseases | Parvovirus B19, Human

Netherlands
Prothya Biosolutions

Completed

C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

Angioedema

Netherlands
Prothya Biosolutions

Completed

Kinetics, Efficacy and Safety of C1-Esteraseremmer-N

Hereditary Angioedema Type I | Angioneurotic Edema

Netherlands
Prothya Biosolutions

Completed

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

Hemophilia B

Netherlands
Prothya Biosolutions

Completed

Efficacy and Safety of IVIG-L in ITP Patients

Purpura, Thrombocytopenic, Idiopathic

Poland
Prothya Biosolutions

Active, not recruiting

Apotransferrin in Atransferrinemia

Congenital Atransferrinemia

Spain, Germany, Italy
Prothya Biosolutions

Terminated

Apotransferrin in Patients With β-thalassemia

β-thalassemia Intermedia

Netherlands
Prothya Biosolutions

Completed

Study Use of PPSB-SD and VP-VI in Patients With Anticoagulant Therapy and Undergoing Acute CPB Surgery

CPB | Oral Anticoagulant Therapy

Belgium
Prothya Biosolutions

Completed

Pharmacokinetics of New HepBQuin

Healthy

Germany
Prothya Biosolutions

Completed

Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml (Nanogam)

Primary Immunodeficiency

Netherlands
Prothya Biosolutions

Completed

Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response (Subklasse)

Infections | IgG Deficiency

Netherlands
Prothya Biosolutions

Completed

C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

Angioedema

Netherlands
Prothya Biosolutions

Completed

Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients

Hypogammaglobulinemia

Netherlands
UMC Utrecht
Prothya Biosolutions

Terminated

Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture (CAESAR)

Sepsis | Inflammation | Trauma | Multiple Organ Dysfunction Syndrome

Netherlands
Erasmus Medical Center
Prothya Biosolutions

Terminated

Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) (ConCoVid-19)

COVID-19

Netherlands
Erasmus Medical Center
Prothya Biosolutions

Unknown

Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS (HS-COST)

Hidradenitis Suppurativa

Netherlands
Prothya Biosolutions
PRA Health Sciences

Completed

Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation

Healthy Volunteers

Netherlands
Prothya Biosolutions
Landsteiner Foundation for Blood Transfusion

Completed

Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia

Neutropenia | MBL-Deficient

Netherlands
Radboud University Medical Center
UMC Utrecht; Prothya Biosolutions

Completed

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II (VECTORII)

Sepsis | Inflammation | Endotoxemia | Innate Immune Response

Netherlands
International Antiviral Therapy Evaluation Center
University Medical Center Groningen; Prothya Biosolutions

Completed

Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection

HIV Infections

Netherlands
Academisch Medisch Centrum - Universiteit van Amsterdam...
Erasmus Medical Center; Prothya Biosolutions

Recruiting

DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema (DUPI REDUCE)

Atopic Dermatitis | Atopic Dermatitis Eczema

Netherlands
Amsterdam UMC, location VUmc
Erasmus Medical Center; St. Antonius Hospital; Rijnstate Hospital; OLVG; Prothya...

Completed

Towards Personalized Dosing of Natalizumab in Multiple Sclerosis (PDNMS)

Multiple Sclerosis

Netherlands
Emergent BioSolutions

Terminated

CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

T-cell Lymphoma
Emergent BioSolutions

Terminated

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

Healthy Volunteers

United States
Emergent BioSolutions

Completed

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Influenza | Bird Flu

United States
Emergent BioSolutions

Completed

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)

Smallpox

United States
Emergent BioSolutions

Completed

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

Smallpox

United States
Emergent BioSolutions

Completed

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Smallpox

United States
Emergent BioSolutions

Completed

VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV

Smallpox Vaccine Adverse Reaction

Canada
Emergent BioSolutions

Completed

Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults

Opioid Overdose

United States
Emergent BioSolutions

Completed

Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)

Zika Virus Infection | Zika Virus Disease

Canada
Emergent BioSolutions

Completed

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

T Cell Lymphoma
Emergent BioSolutions

Enrolling by invitation

BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients

Botulism
Emergent BioSolutions

Completed

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Typhoid

United States
Emergent BioSolutions

Completed

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

Influenza A H3N2 | Influenza A H1N1

United States, Spain, Canada, Puerto Rico
Emergent BioSolutions

Completed

Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel

Smallpox

United States
Emergent BioSolutions

Completed

ACAM2000® Myopericarditis Registry

Myocarditis | Pericarditis

United States
Emergent BioSolutions

Completed

Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Smallpox

United States
Emergent BioSolutions

Completed

A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

Anthrax Infection

United States
Emergent BioSolutions

Completed

Safety Surveillance Study of ACAM2000® Vaccinia Vaccine

Smallpox

United States
Emergent BioSolutions

Completed

Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)

Human Influenza

Australia
PX Biosolutions

Completed

Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity

Cervical Cancer | Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Ovarian Serous Adenocarcinoma | Undifferentiated Carcinoma of Ovary | Cervical Intraepithelial Neoplasia, Grade 3

Australia
Immune Biosolutions Inc

Completed

Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness

COVID-19

South Africa, Brazil
Ampel BioSolutions, LLC

Completed

A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE (RIFLE)

Fatigue | Lupus Erythematosus, Systemic | Lupus Erythematosus

United States
Erasmus Medical Center
Leiden University Medical Center; ZonMw: The Netherlands Organisation for Health... and other collaborators

Terminated

Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study) (CoV-Early)

Covid19

Netherlands
Ampel BioSolutions, LLC

Recruiting

Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE) (ReLATE)

Lupus Erythematosus, Systemic

United States
Emergent BioSolutions
GlaxoSmithKline

Completed

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

Infections, Bacterial

United States
Immune Biosolutions Inc

Completed

Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

COVID-19

South Africa, Ukraine
Immune Biosolutions Inc

Completed

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

COVID-19

Ukraine, South Africa
Pantec Biosolutions AG

Unknown

Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis

Psoriatic Plaque

Switzerland

Clinical Trials Sponsored by Prothya Biosolutions

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations